Adds details on vaccine in paragraph 2, details on disease in paragraphs 3 & 4
Feb 28 (Reuters) - Britain's health regulator said on Friday it has approved Moderna's MRNA.O vaccine for respiratory syncytial virus in adults 60 years and older.
The shot, branded as mRESVIA, is for the prevention of lower respiratory tract disease in older adults, the Medicines and Healthcare products Regulatory Agency (MHRA) said.
RSV is a common virus that spreads very easily and causes infections that can be mild, with cold-like symptoms, but can also cause more serious problems, such as lung infections and pneumonia.
Older adults are at risk of more serious complications that could lead to hospital admission and even death.
GSK's GSK.L vaccine Arexvy and Pfizer's <PFE.N> shot Abrysvo are approved for use in individuals over the age of 60 in the UK.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar and Shailesh Kuber)
((Sriparna.Roy@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。